Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cue BiopharmaCUE +8.53%45 EV-to-EBITDA is -7.49 as of Jul. 31, 2026. GuruFocus rates CUE with a GF Score™ of 45/100. The stock has 3 warning signs investors should review. Among 411 Biotechnology companies, Cue Biopharma ranks worse than 243308.76% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cue Biopharma's enterprise value is $114.75 Mil.
Cue Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-15.32 Mil. Therefore, Cue Biopharma's EV-to-EBITDA for today is -7.49.
The historical rank and industry rank for Cue Biopharma's EV-to-EBITDA or its related term are showing as below:
CUE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.03 Med: -2.58 Max: -0.13
Current: -7.49
During the past 11 years, the highest EV-to-EBITDA of Cue Biopharma was -0.13. The lowest was -20.03. And the median was -2.58.
CUE's EV-to-EBITDA is ranked worse than 100% of 411
companies
in the Biotechnology industry
Industry Median: 12.05
vs CUE: -7.49
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cue Biopharma's PE Ratio (TTM) for today is calculated as:
Cue Biopharma's share price for today is $30.40.
Cue Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.580.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cue Biopharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cue Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cue Biopharma EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cue Biopharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cue Biopharma's EV-to-EBITDA falls into.
Cue Biopharma's current Enterprise Value is $114.75 Mil.
Cue Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cue Biopharma (CUE) has a EV-to-EBITDA of -7.49 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cue Biopharma. According to the industry distribution chart, Cue Biopharma ranks #999999 out of 411 companies in the Biotechnology industry.
Is Cue Biopharma's EV-to-EBITDA too high?
Cue Biopharma's current EV-to-EBITDA is -7.49. Based on the distribution chart, Cue Biopharma ranks #999999 out of 411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cue Biopharma has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's EV-to-EBITDA compare to CNTB and CDXS?
According to the Biotechnology industry distribution chart, Cue Biopharma ranks #999999 out of 411 companies for EV-to-EBITDA. This places Cue Biopharma in the lower half of its industry. The industry median EV-to-EBITDA is 12.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.05, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cue Biopharma. For the Biotechnology industry, the median EV-to-EBITDA is 12.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cue Biopharma's current EV-to-EBITDA is -7.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Cue Biopharma (CUE) has a current EV-to-EBITDA of -7.49. The current EV-to-EBITDA is -7.49. Cue Biopharma's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cue Biopharma (CUE), the current EV-to-EBITDA is -7.49 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
45GF Score
Get the complete analysis for CUE
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CUE has been successfully added to your 
